How an outsider crept into Eli Lilly's top ranks — and plans to drive its business forward

Jacob Van Naarden has upended the drug giant's cancer pipeline

The defining moment arrived in a simple white envelope.

On December 20, 2018, Jacob Van Naarden, then chief operating officer of biotech company Loxo Oncology, accompanied CEO Josh Bilenker to their Stamford, Connecticut headquarters for what they believed would be an informal meeting with Levi Garraway, Eli Lilly's head of oncology research. Both executives anticipated a routine exchange of company updates and industry insights.

The reality proved dramatically different. "We walk into our conference room, and there's like a room full of Lilly people," Van Naarden recounted to STAT. The meeting included Lilly's chief scientific officer, head of business development, oncology division leader, and chief financial officer—a formidable delegation that immediately signaled serious intent.

After brief pleasantries, Lilly representatives presented their proposition in the form of a white envelope containing acquisition terms. "If I'd known it was going to be this kind of meeting, I would have put on a jacket," Bilenker remarked. "But this looks like something my board needs to hear about."

The encounter concluded in under 20 minutes, leaving the Lilly team to their lunch as Van Naarden and Bilenker departed to process the unexpected development. One month later, Eli Lilly completed its acquisition of Loxo Oncology for $8 billion in cash.

This transaction exemplifies a strategy more common in technology than pharmaceuticals. While "acqui-hires"—acquisitions primarily motivated by talent acquisition—are standard practice in tech, they represent an unusual approach in the pharmaceutical sector.

The investment has yielded substantial returns beyond Loxo's cancer drug portfolio and research capabilities. The acquisition brought key leadership talent that has significantly influenced Lilly's strategic direction. While Bilenker departed in 2021 to establish Treeline Biosciences, which has secured $622 million in venture capital according to PitchBook data, Van Naarden has ascended to unprecedented influence within Lilly's organization.

Van Naarden now oversees Eli Lilly's entire oncology division, encompassing both research and development as well as commercial operations. Additionally, as of 2025, he assumed responsibility for the company's business development function, directing all dealmaking activities for what has become the pharmaceutical industry's most valuable publicly traded company by market capitalization.

This remarkable trajectory from biotech COO to pharmaceutical industry leader illustrates the transformative potential of strategic acquisitions when executed with talent retention as a primary objective.